Welcome to AMYPAD!

We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
Developing and submitting a research protocol for a multicenter clinical study
Developing and submitting a research protocol for a multicenter clinical study 26 Feb 2018 The development of the AMYPAD DPMS protocol was led by WP3. It was approved in Switzerland at the beginning of January.......
Interview with Elisa Canzoneri
Interview with Elisa Canzoneri 26 Feb 2018 I worked as Clinical Project Manager in the UNIGE team until October 2017, working in strict collaboration with WP3 leadership......
Interview with Giovanni Frisoni
Interview with Giovanni Frisoni 26 Feb 2018 I am PI of the diagnostic and patient management study (DPMS), a Randomized Control Trial (RCT) aiming to test the incremental diagnostic confidence......
"At this moment, there is a massive effort to better understand the natural history of Alzheimer’s Disease (AD), as well to improve its management. These efforts wish to increase the chances of success for future clinical trials by allowing them to target populations at the early stages of the disease, when the damage could still be reversed. AMYPAD comes to provide valuable insight on a fundamental piece of the AD puzzle: the accumulation of β-amyloid plaques. We will be doing so by determining the role and value of amyloid imaging in disease diagnosis, prognosis, and potential for treatment monitoring - which will be a crucial step forward in the global fight against AD.” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.